Neurodegenerative Disease & EEG: Listening for the Earliest Signs of Alzheimer’s and Parkinson’s

Neurodegenerative diseases rarely announce themselves loudly. Instead, they begin quietly—through subtle cognitive changes, mild motor shifts, or barely noticeable alterations in brain rhythms.

For EEG technologists, those changes are often visible long before they become clinically obvious.

Alzheimer’s disease (AD) and Parkinson’s disease (PD) have traditionally been diagnosed through clinical evaluation and imaging. However, EEG is increasingly emerging as a tool for early detection, disease monitoring, and biomarker discovery. As research continues to evolve, EEG may no longer be viewed only as a seizure tool—but as a window into the earliest stages of neurodegeneration. 

Why EEG Is Uniquely Positioned in Neurodegenerative Disease Detection

Neurodegenerative diseases disrupt neural networks, synaptic communication, and cortical connectivity. EEG captures these changes directly—often before structural imaging reveals abnormalities.

Compared to other modalities, EEG offers:

• Real-time measurement of brain function

• Sensitivity to network-level dysfunction

• Low cost and accessibility

• Ability to track longitudinal changes over time

Unlike MRI or PET scans, which highlight structure or metabolism, EEG reflects functional deterioration—making it especially valuable in early-stage conditions such as mild cognitive impairment (MCI) or prodromal Alzheimer’s disease. 

EEG Findings in Alzheimer’s Disease: The Signature of Slowing

One of the most consistent EEG findings in Alzheimer’s disease is progressive slowing of cortical rhythms.

Core EEG Features in Alzheimer’s Disease

• Increased delta and theta activity

• Reduced alpha and beta activity

• Slowing of the posterior dominant rhythm (PDR)

• Decreased interhemispheric coherence

• Disrupted functional connectivity

These changes reflect synaptic loss and impaired cortical communication, particularly in temporoparietal regions. 

What This Means Clinically

Research has shown that:

• Patients with MCI who later develop Alzheimer’s often demonstrate abnormal theta/alpha ratios years before diagnosis

• Reduced alpha power correlates with memory decline

• EEG slowing parallels cognitive deterioration on neuropsychological testing

From a technologist’s perspective, this may appear as subtle findings—slightly slowed PDR, increased diffuse theta, or reduced posterior alpha—long before a formal diagnosis is made. 

Beyond Visual EEG: The Role of Quantitative EEG (qEEG)

Traditional EEG interpretation is only part of the story. Modern neurodegenerative research increasingly relies on quantitative EEG (qEEG).

Key qEEG Metrics Include:

• Spectral power analysis

• Coherence and phase synchronization

• Network topology (graph theory)

• Entropy and complexity measures

Emerging findings suggest:

• Increased theta/alpha ratios may serve as early biomarkers of Alzheimer’s disease

• Reduced EEG complexity reflects loss of network flexibility

• Altered connectivity patterns indicate disrupted cortical communication

Machine learning models that combine these EEG features are showing promising accuracy in distinguishing Alzheimer’s disease, MCI, and normal aging. 

EEG in Parkinson’s Disease: More Than a Movement Disorder

Parkinson’s disease is often viewed primarily as a movement disorder—but EEG reveals broader cortical involvement.

Common EEG Findings in Parkinson’s Disease

• Diffuse slowing, especially in later stages

• Reduced beta activity in motor networks

• Altered gamma oscillations

• Disrupted frontoparietal connectivity

Patients with Parkinson’s disease dementia may show EEG patterns similar to Alzheimer’s disease, including increased theta and delta activity. 

Clinical Relevance

EEG abnormalities in Parkinson’s disease have been associated with:

• Cognitive decline

• Hallucinations and neuropsychiatric symptoms

• Disease progression

• Response to dopaminergic therapy

These findings highlight that EEG can provide insight beyond motor symptoms—into the broader neurological impact of the disease.

Why Subtle EEG Changes Matter

Behind every EEG tracing is a patient whose symptoms may not yet have a clear diagnosis.

Consider an older adult referred for evaluation of “memory changes” or “episodes of confusion.” The EEG may show mild diffuse slowing—nothing dramatic, nothing overtly epileptiform, but not entirely normal.

In the past, these findings might have been labeled as nonspecific. Today, they are increasingly recognized as potential early markers of neurodegenerative disease. 

Early recognition can provide:

• Earlier intervention opportunities

• More accurate prognostic information

• Access to clinical trials

• Time for patients and families to plan

Clinical Challenges and Limitations

Despite its growing role, EEG is not yet a standalone diagnostic tool for neurodegenerative diseases.

Key challenges include:

• Overlap between normal aging and pathological slowing

• Effects of medications, sleep state, and metabolic factors

• Individual variability in EEG patterns

• Lack of standardized diagnostic thresholds

For example, a slowed PDR in an older adult does not automatically indicate Alzheimer’s disease. Clinical context remains essential. 

This is why current approaches emphasize multimodal evaluation, combining EEG with imaging, genetics, and neuropsychological testing.

What This Means for EEG Technologists

The role of EEG technologists is evolving alongside this research.

Key Takeaways:

• Pay attention to background rhythms, not just epileptiform activity

• Document subtle changes in frequency, symmetry, and organization

• Recognize patterns of diffuse slowing and reduced alpha activity

• Understand the effects of aging, medications, and vigilance state

• Appreciate that “nonspecific” findings may have clinical importance

EEG technologists are often the first to observe changes that suggest early neurodegeneration. In many cases, your recording becomes part of the earliest evidence that something deeper is occurring. 

The Future: EEG as an Early Warning System

As machine learning, network neuroscience, and large-scale EEG datasets continue to advance, EEG may become an increasingly powerful screening tool.

Future possibilities include:

• Identifying patients at risk for Alzheimer’s disease before symptoms appear

• Guiding personalized treatment strategies

• Tracking disease progression through longitudinal EEG monitoring

The brain does not suddenly become neurodegenerative—it changes gradually. EEG allows us to observe those changes in real time. 

Final Thoughts

For EEG technologists, this shift represents something significant.

Our work is no longer limited to detecting seizures. It is about recognizing the brain’s most subtle signals—changes that may represent the earliest stages of disease.

Because sometimes, the quietest patterns carry the most important meaning.

And in those moments, EEG is not just recording brain activity—

it is listening for what comes next.

SourcesJeong, J. (2004). EEG dynamics in patients with Alzheimer’s disease. Clinical Neurophysiology,

115(7), 1490–1505.Dauwels, J., Vialatte, F., & Cichocki, A. (2010). Diagnosis of Alzheimer’s disease from EEG signals: Where are we standing? Current Alzheimer Research, 7(6), 487–505.Babiloni, C., et al. (2016). Abnormal fronto-parietal coupling of brain rhythms in mild cognitive impairment. NeuroImage: Clinical, 11, 373–381.Stam, C. J., et al. (2006). Graph theoretical analysis of functional connectivity in Alzheimer’s disease. Brain, 130(1), 213–224.Bosboom, J. L. W., et al. (2006). Resting-state oscillatory brain dynamics in Parkinson’s

disease. Clinical Neurophysiology, 117(11), 2521–2531.Olde Dubbelink, K. T. E., et al. (2014). Disrupted brain network topology in Parkinson’s disease. Brain, 137(1), 197–207.Cassani, R., et al. (2018). Machine learning for EEG-based Alzheimer’s disease diagnosis: An overview. Journal of Neural Engineering, 15(5), 051001.

Gouw, A. A., et al. (2017). EEG spectral analysis as a biomarker for cognitive decline. Alzheimer’s Research & Therapy, 9(1), 11.